Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan

Trial Profile

An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 28 Sep 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Glatiramer acetate (Copaxone) subcutaneous injection 20 mg syringe for the treatment of multiple sclerosis. The approval is based on the results of this and three other overseas clinical trials conducted by Teva in patients with relapsing- remitting multiple sclerosis.
    • 30 Jul 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top